Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neisseria meningitidis Infections - Pipeline Review, H2 2018, provides an overview of the Neisseria meningitidis Infections (Infectious Disease) pipeline landscape.
Neisseria Meningitidis is a severe bacterial infection of the bloodstream and meninges (a thin lining covering the brain and spinal cord). Symptoms include fever, neck stiffness, joint pain, nausea, confusion and drowsiness. Risk factors include age, smoking, mucosal lesions, overcrowding, climatic conditions such as dry seasons or prolonged drought and dust storms and concomitant respiratory infections.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neisseria meningitidis Infections - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neisseria meningitidis Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 4, 3, 9, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.
Neisseria meningitidis Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Neisseria meningitidis Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neisseria meningitidis Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neisseria meningitidis Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neisseria meningitidis Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neisseria meningitidis Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neisseria meningitidis Infections - Overview
Neisseria meningitidis Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Neisseria meningitidis Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neisseria meningitidis Infections - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
Biological E Ltd
China National Pharmaceutical Group Corp
Chongqing Zhifei Biological Products Co Ltd
GlaxoSmithKline Plc
Hualan Biological Engineering Inc
ImmunoBiology Ltd
Johnson & Johnson
MGB Biopharma Ltd
Pfizer Inc
Sanofi Pasteur SA
Serum Institute of India Ltd
Tianjin CanSino Biotechnology Inc
Wellstat Vaccines LLC
Neisseria meningitidis Infections - Drug Profiles
(diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Haemophilus influenzae B + Neisseria meningitidis [serotypes A, C, Y, W135]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MenBioVax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, B, C] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W, Y] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W-135, Y] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes A, C] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal [serotypes C, Y] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
meningococcal vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGBBP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCL-195 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neisseria meningitidis [serotype B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06886992 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neisseria meningitidis Infections - Dormant Projects
Neisseria meningitidis Infections - Discontinued Products
Neisseria meningitidis Infections - Product Development Milestones
Featured News & Press Releases
Apr 23, 2018: Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years
Mar 06, 2018: TRUMENBA (Meningococcal Group B Vaccine) Now Available In Canada
Dec 13, 2017: Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Data Published In New England Journal Of Medicine Demonstrate The Vaccine’s Immunogenicity
Sep 12, 2017: TGA approves MENVEO vaccine to help protect babies from two months old from meningococcal disease
Jul 11, 2017: Recall of MENVEO [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] Solution for intramuscular injection
May 30, 2017: European Commission Approves Pfizer's Trumenba To Help Prevent Meningococcal Group B Disease In Adolescents And Adults
Mar 24, 2017: Pfizer Receives Positive CHMP Opinion for TRUMENBA for Prevention of Meningococcal Group B Disease
Mar 24, 2017: GSK Announces Availability of Menveo (meningococcal ACWY vaccine)
Oct 19, 2016: CDC Advisory Committee on Immunization Practices Votes to Recommend New Dosing Schedule for Vaccination with TRUMENBA (Meningococcal Group B Vaccine)
May 20, 2016: Pfizer Announces European Medicines Agency Acceptance For Review Of Marketing Authorization Application For TRUMENBA (Meningococcal Group B Vaccine)
May 13, 2016: Pfizer Presents Results From Two Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Studies At The European Society For Pediatric Infectious Diseases Meeting
Oct 09, 2015: Pfizer’s Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA When Co administered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate and Tetanus, Diphtheria and Pertussis Vaccines in Adolescents
Aug 21, 2015: Pfizer Announces Positive Top line Results Of Two Phase 3 Studies Of TRUMENBA (Meningococcal Group B Vaccine)
Jun 24, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination including TRUMENBA for Adolescents and Young Adults 16 through 23 Years of Age
Feb 26, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Neisseria meningitidis Infections, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Neisseria meningitidis Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2018
Neisseria meningitidis Infections - Pipeline by Biological E Ltd, H2 2018
Neisseria meningitidis Infections - Pipeline by China National Pharmaceutical Group Corp, H2 2018
Neisseria meningitidis Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2018
Neisseria meningitidis Infections - Pipeline by GlaxoSmithKline Plc, H2 2018
Neisseria meningitidis Infections - Pipeline by Hualan Biological Engineering Inc, H2 2018
Neisseria meningitidis Infections - Pipeline by ImmunoBiology Ltd, H2 2018
Neisseria meningitidis Infections - Pipeline by Johnson & Johnson, H2 2018
Neisseria meningitidis Infections - Pipeline by MGB Biopharma Ltd, H2 2018
Neisseria meningitidis Infections - Pipeline by Pfizer Inc, H2 2018
Neisseria meningitidis Infections - Pipeline by Sanofi Pasteur SA, H2 2018
Neisseria meningitidis Infections - Pipeline by Serum Institute of India Ltd, H2 2018
Neisseria meningitidis Infections - Pipeline by Tianjin CanSino Biotechnology Inc, H2 2018
Neisseria meningitidis Infections - Pipeline by Wellstat Vaccines LLC, H2 2018
Neisseria meningitidis Infections - Dormant Projects, H2 2018
Neisseria meningitidis Infections - Dormant Projects, H2 2018 (Contd..1), H2 2018
Neisseria meningitidis Infections - Dormant Projects, H2 2018 (Contd..2), H2 2018
Neisseria meningitidis Infections - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Neisseria meningitidis Infections, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
